The NIH and FDA’s approach to CRIS- PR-based human gene therapy oversight now include long-term patient tracking, extending up to 15 years post-treatment for certain genetic modifications.
A trend is graded on whether the publisher keeps it, never as a hit or a miss (D6, D33).